Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 65(7): 5300-5316, 2022 04 14.
Article in English | MEDLINE | ID: mdl-35302767

ABSTRACT

Bruton's tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways as an essential intracellular signaling element, participating in both adaptive and immune responses. Currently approved BTK inhibitors are irreversible covalent inhibitors and limited to oncology indications. Herein, we describe the design of covalent reversible BTK inhibitors and the discoveries of PRN473 (11) and rilzabrutinib (PRN1008, 12). These compounds have exhibited potent and durable inhibition of BTK, in vivo efficacy in rodent arthritis models, and clinical efficacy in canine pemphigus foliaceus. Compound 11 has completed phase 1 trials as a topical agent, and 12 is in phase 3 trials for pemphigus vulgaris and immune thrombocytopenia.


Subject(s)
Protein Kinase Inhibitors , Signal Transduction , Agammaglobulinaemia Tyrosine Kinase , Animals , Dogs , Protein Kinase Inhibitors/pharmacology , Protein Kinase Inhibitors/therapeutic use
2.
Immunohorizons ; 5(7): 581-589, 2021 07 29.
Article in English | MEDLINE | ID: mdl-34326199

ABSTRACT

The expression of Bruton tyrosine kinase (BTK) in B cells and innate immune cells provides essential downstream signaling for BCR, Fc receptors, and other innate immune cell pathways. The topical covalent BTK inhibitor PRN473 has shown durable, reversible BTK occupancy with rapid on-rate and slow off-rate binding kinetics and long residence time, resulting in prolonged, localized efficacy with low systemic exposure in vivo. Mechanisms of PRN473 include inhibition of IgE (FcεR)-mediated activation of mast cells and basophils, IgG (FcγR)-mediated activation of monocytes, and neutrophil migration. In vivo, oral PRN473 was efficacious and well tolerated in the treatment of canine pemphigus foliaceus. In this study, we evaluated in vitro selectivity and functionality, in vivo skin Ab inflammatory responses, and systemic pharmacology with topically administered PRN473. Significant dose-dependent inhibition of IgG-mediated passive Arthus reaction in rats was observed with topical PRN473 and was maintained when given 16 h prior to challenge, reinforcing extended activity with once-daily administration. Similarly, topical PRN473 resulted in significant dose-dependent inhibition of the mouse passive cutaneous anaphylaxis IgE-mediated reaction. Multiday treatment with topical PRN473 in rodents resulted in low-to-no systemic accumulation, suggesting that efficacy was mainly due to localized exposure. Reduced skin Ab inflammatory activity was also confirmed with oral PRN473. These preclinical studies provide a strong biologic basis for targeting innate immune cell responses locally in the skin, with rapid onset of action following once-daily topical PRN473 administration and minimal systemic exposure. Dose-dependent inhibition in these preclinical models of immune-mediated skin diseases support future clinical studies.


Subject(s)
Agammaglobulinaemia Tyrosine Kinase , Arthus Reaction , Passive Cutaneous Anaphylaxis , Protein Kinase Inhibitors , Skin Diseases , Animals , Female , Humans , Mice , Rats , Administration, Cutaneous , Administration, Oral , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Arthus Reaction/drug therapy , Arthus Reaction/immunology , Arthus Reaction/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Passive Cutaneous Anaphylaxis/drug effects , Protein Kinase Inhibitors/administration & dosage , Skin/drug effects , Skin/immunology , Skin/pathology , Skin Diseases/drug therapy , Skin Diseases/immunology , Skin Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...